- With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC's, Monoclonal Antibodies,
Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy.
Lastly, our immuno-oncology platform, which includes Libtayo and our portfolio of
bispecific antibodies, is progressing well, with the most advanced bispecific program, REGN1979 (CD20xCD3), entering a potentially pivotal Phase 2 trial in follicular lymphoma."
The company's proprietary technology platform enables the design of
bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.
In addition, Zymeworks' Azymetric platform enables the transformation of monospecific antibodies into
bispecific antibodies, giving the antibodies the ability to simultaneously bind two different targets.
Sanofi will pay Regeneron $462 million representing the balance of payments due under the original Immuno-oncology Agreement, which covers discovery program costs for the last quarter of 2018 and up to $120 million in development costs for the two selected clinical-stage
bispecific antibodies, plus the termination fee for the other programs under the original agreement.
But at the same time that monoclonal antibodies have hogged the spotlight, their distant cousins,
bispecific antibodies, have been floating around.
Their topics include the humanization of antibodies, affinity maturation approaches for antibody lead optimization, antibody expression from bacteria to transgenic animals, the design and application of immunoconjugates for cancer therapy, and dual-targeting
bispecific antibodies as new therapeutic modalities for cancer.
However, most tumors are dependent on more than one pathway, which implies rational antibody combinations or
bispecific antibodies. In our presentation, we will illustrate the use of kinetic computational models that capture protein-protein interactions to explore antibody combinations vs.
Genmab's DuoBody platform creates human
bispecific antibodies, which bind to two different epitopes, on the same or different disease targets.
DVD-Ig, which stands for dual-variable-domain immunoglobulin, is also known as
bispecific antibodies. It involves building therapeutic monoclonal antibodies in the laboratory to latch onto two different targets in the body at one time.
"This new patented technology permits us to expand our cancer therapeutics, especially the treatment of non-Hodgkin's lymphoma with
bispecific antibodies against such markers as CD20 and CD22 expressed by such tumors," commented Cynthia L.